To assess whether IL17A depletion augments vaccine‐induced tumour immunity, KPC/IL17A+/+ and KPC/IL17A−/− mice were vaccinated with ENO1‐pVAX starting at 2 months of age (Figure 2A).14 This evidence concerns the gene IL17A and neoplasm.